louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03085186: Treatment With Crizotinib Single Patient Expanded Access IND 134375
Official title: Treatment With Crizotinib Single Patient Expanded Access IND 134375
Study type: EXPANDED_ACCESS
Overall status: NO_LONGER_AVAILABLE
Conditions: Inflammatory Myofibroblastic Tumour
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2017-03-21
Sex: MALE
Minimum age (years): 2
Maximum age (years): 2
Standard ages: CHILD

Brief summary: Two year old male with a new diagnosis of Inflammatory Myofibroblastic Tumour. The patient presented with 2 months of intermittent fever and 1-2 weeks of abdominal distention and constipation. An abdominal mass was palpable on exam and US concerning was for neoplasm of abdomen.

Treatment with Crizotinib will be utilized to reduce the size of the lesion and create more optimal tissue plains between vital structures prior to attempted surgical resection would greatly reduce potential morbidity for this patient.


Eligibility criteria: Inclusion Criteria:

* This treatment plan is intended for the use of Crizotinib in the treatment of a single patient with Inflammatory Myofibroblastic Tumour

Exclusion Criteria:

* Not applicable as Expanded Access only includes one patient

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00596986: Getting Biased Treatment Study: How Psychotherapy and Antidepressants Change Brain Activity in Chronic Depression
Official title: Impact of Therapeutical Strategies on Emotional Processing in Depression: Neurofunctional and Clinical Issues in the Context of Affective Bias
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Depression
Keywords: Depression
Duloxetine
Psychotherapy
Magnetic Resonance Imaging
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
Collaborators: name: German Federal Ministry of Education and Research
First posted: 2008-01-17
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to determine how psychotherapy and pharmacotherapy respectively change brain activity in patients suffering from chronic depression.


Eligibility criteria: Inclusion Criteria:

* Chronic Depression (Double Depression, Chronic MDE, MDE with incomplete remission)
* HAMD-24\>20

Exclusion Criteria:

* Concurrent Psychotherapy or Psychopharmacotherapy
* Previous Non-Response to Duloxetine
* Non-Response to three Antidepressants of two different groups given at adequate doses or Non-Response to two empirically tested forms of Psychotherapy in the current Depressive Episode
* Serious Psychiatric comorbidity
* Serious Neurologic comorbidity
* Contraindications to Duloxetine
* Contraindications to fMRI

Primary outcomes:
measure: Neuroimaging Data (fMRI)
timeFrame: Before and After Therapy
Secondary outcomes:
measure: HAMD
timeFrame: Weekly
measure: Salivary Cortisol
timeFrame: Before and After Therapy
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charité Universitätsmedizin
Study officials:
affiliation: Dept. of Psychiatry, Campus Benjamin Franklin, Charité Berlin, Germany
name: Isabella Heuser, Prof. Dr. med. Dipl. Psych.
role: STUDY_CHAIR
affiliation: Department of Psychiatry, Campus Benjamin Franklin, Charité Berlin, Germany
name: Michael Colla, Dr. med.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04212286: Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC
Official title: A Single-Center, Prospective Study Comparing the Diagnostic Efficiencies of Contrast-Enhanced Ultrasound and EOB Contrast-Enhanced Magnetic Resonance Imaging for Lesions With Diameters ≤ 2cm in Patients With High Risk of HCC
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hepatocellular Cancer
Liver Cirrhoses
Diagnoses Disease
Keywords: Hepatocellular Cancer
Contrast-enhanced ultrasound
EOB-MRI
Diagnostic Efficacy
Lead sponsor: Tianjin Third Central Hospital
Sponsor class: OTHER
First posted: 2019-12-26
Enrollment: 115
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: HCC is a serious threat to the health of people. Accurate diagnosis of early HCC by imaging allows patients to obtain proper treatment. However, for lesions with diameters ≤2 cm, the tumor blood supply is not fully established, and there may be no typical manifestation on the image. In addition, atypical enhanced patterns caused by liver cirrhosis may also hinder imaging diagnosis of HCC. Therefore, early diagnosis of HCC in the context of cirrhosis remains a major clinical problem.

Contrast-enhanced Ultrasound (CEUS) and MRI Contrast-enhanced Magnetic Resonance Imaging (CEMRI) are common diagnostic imaging methods. Till now, there is still lack of a detailed investigation comparing the diagnostic efficacies of CEUS and EOB-MRI for micro HCC in the context of cirrhosis. Therefore, this study aims to analyze the imaging patterns in CEUS and EOB-MRI for liver lesions with diameters ≤ 2 cm among patients with high risk of HCC, and to compare the diagnostic efficacies of EOB-MRI and CEUS for early-stage HCCs.


Eligibility criteria: Inclusion Criteria:

1. Patients are at high risk of HCC.
2. The ages of patients are between 18 and 80.
3. Patients are with solid liver lesion(s) ≤ 2 cm detected by imaging scan (US/CT/MRI).
4. The number of lesions is less than or equal to 3.
5. Patient is able and willing to receive CEUS and EOB-MRI examinations within 30 days.
6. Patient signs the informed consent.

Exclusion Criteria:

1. Patient is with lesions confirmed by pathology or follow-up, or hemangiomas.
2. Patient is with lesions already undergoing local treatment, including thermal ablation or TACE.
3. Patient is with severe cardiopulmonary insufficiency.
4. Patient is a pregnant or breastfeeding women.
5. Patient is considered to be unsuitable to participate in the study.

Primary outcomes:
measure: The sensitivity, specificity and accuracy of CEUS and EOB-MRI
timeFrame: 6 to 12 months
Secondary outcomes:
measure: The sensitivity, specificity and accuracy of combined CEUS and EOB-MRI
timeFrame: 6 to 12 months
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Tianjin Third Central Hospital
state: Tianjin
Study officials:
affiliation: Tianjin Third Central Hospital
name: Xiang Jing, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05712486: Manual Therapy for the Treatment of Athletic Pubalgia
Official title: Effects on Pain Anda Range of Motion of High Force Lateral Distraction Mobilization of the Hip in Athletes With Hip-related Groin Pain. A Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Osteitis Pubis
Lead sponsor: University of Valladolid
Sponsor class: OTHER
First posted: 2023-02-03
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Athletic osteitis pubis is a high prevalent pathology among athletes, especially in those who make quick change of direction of the movement, like runners or footballers. Despite the fact that there is evidence about conservative treatments, there is a lack of evidence about manual therapy (MT) techniques applied in isolation and its consequences in pain and range of movement. The investigators decided to conduct a randomized controlled trial to compare the effects of a MT technique with placebo technique.


Eligibility criteria: Inclusion Criteria:

* Athletes diagnosed with osteitis pubis stage 1 with at least 3 months of evolution.
* Internal rotation ROM limited.
* Positive provocation pain tests.

Exclusion Criteria:

* Pain due to intraarticular hip pathology.
* Hip pain due to inflamatory diseases.
* Previous surgical interventions in hip, pelvis or lumbar spine.
* MRI results or provocation pain tests inconcluyent.

Primary outcomes:
measure: Actual PAIN
timeFrame: Baseline
measure: Actual PAIN
timeFrame: after to two weeks of treatment
measure: Actual PAIN
timeFrame: 3 months follow-up
measure: Last week PAIN
timeFrame: Baseline
measure: Last week PAIN
timeFrame: after to two weeks of treatment
measure: Last week PAIN
timeFrame: 3 months follow-up
Secondary outcomes:
measure: Range of Movement (ROM)
timeFrame: Baseline
measure: Range of Movement (ROM)
timeFrame: after to two weeks of treatment
measure: Range of Movement (ROM)
timeFrame: 3 months follow-up
measure: Global Rating of Change
timeFrame: after to two weeks of treatment
measure: Global Rating of Change
timeFrame: 3 months follow-up
measure: Group of treatment assignment
timeFrame: after to two weeks of treatment
measure: Group of treatment assignment
timeFrame: 3 months follow-up
Other outcomes:
Locations:
city: Soria
country: Spain
facility: Silvia Lahuerta Martín
Study officials:
affiliation: University of Valladolid
name: Silvia Lahuerta Martín
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00199186: Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)
Official title: A Randomized, Multicenter Open Label Phase II Study to Determine the Safety and Efficacy of Induction Therapy With Imatinib in Comparison With Standard Induction Chemotherapy in Elderly (> 55 Years) Patients With Ph Positive Acute Lymphoblastic Leukemia (ALL)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Philadelphia Positive Acute Lymphoblastic Leukemia
Lymphoid Blastic Phase of Chronic Myeloid Leukemia
Lead sponsor: Johann Wolfgang Goethe University Hospital
Sponsor class: OTHER
First posted: 2005-09-20
Sex: ALL
Minimum age (years): 56
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aims of the study are to determine whether single agent imatinib (STI571; Glivec) is more effective as up-front remission induction therapy than conventional multi-agent induction chemotherapy for elderly patients with Philadelphia positive (Ph+)ALL, whether this treatment is better tolerated, and whether subsequent combination therapy with imatinib and chemotherapy of approximately a 1 year duration is tolerable and effective with respect to maintaining remissions.


Eligibility criteria: Inclusion Criteria:

* Male or female patients
* Age \> 55 years (biological age)
* Diagnosis of Ph1 chromosome-positive ALL (pre-B, common- or pre-pre-B ALL)
* Newly diagnosed, lymphoid blast crisis of chronic myeloid leukemia
* Only pre-phase chemotherapy prior to study start
* World Health Organization (WHO) status 0, 1 or 2
* Voluntary written informed consent

Exclusion Criteria:

* Creatinine levels more than 2 x the upper limit of normal (ULN)
* Total serum bilirubin more than 1.5 x the ULN
* AST (SGOT) or ALT (SGPT) more than 5 x the ULN
* Any other prior antineoplastic treatment except for pre-phase chemotherapy
* Active central nervous system (CNS) leukemia
* New York Heart Association (NYHA) grade 3/4 cardiac disease
* Active severe infection
* Serious concomitant medical condition
* Patients with a history of non-compliance to medical regimens

Primary outcomes:
measure: Remission rate after induction therapy
Secondary outcomes:
measure: Mortality rate during induction
measure: Severe adverse events during induction
measure: Efficacy of salvage therapy after crossover
measure: Levels of minimal residual disease
measure: Incidence of relapse
measure: Remission duration
measure: Disease free survival
measure: Overall survival
measure: Frequency of point mutations in the BCR-ABL gene
Other outcomes:
Locations:
city: Frankfurt/Main
country: Germany
facility: Medizinische Klinik II, Johann Wolfgang Goethe Universität
Study officials:
affiliation: Medizinische Klinik II, Johann Wolfgang Goethe Universität
name: Oliver G Ottmann, M.D.
role: STUDY_CHAIR
References:
Clinical trial NCT00446186: MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)
Official title: Mk0476 Phase II Dose Finding Study -Allergic Rhinitis-
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Rhinitis Allergic
Lead sponsor: Organon and Co
Sponsor class: INDUSTRY
First posted: 2007-03-12
Enrollment: 945
Sex: ALL
Minimum age (years): 15
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The clinical study evaluates the efficacy and safety of MK0476 in adult patients with allergic rhinitis.


Eligibility criteria: Inclusion Criteria:

* Adult patients with seasonal allergic rhinitis

Exclusion Criteria:

* Patients who have nasal diseases (e.g., nasal polyp, septonasal arcuation, hypertrophic rhinitis), upper respiratory infection, sinusitis, infectious rhinitis, ocular infection and those disease severe enough to interfere with assessment of effectiveness
* Patients who have rhinitis medicamentosa, or nonallergic rhinitis (e.g., vasomotor rhinitis, eosinophilia rhinitis)
* Patient has a disease of the cardiovascular, hepatic, renal, hematologic systems, or other severe disease

Primary outcomes:
measure: The change from baseline in the composite nasal symptoms score (average over the 2-week treatment period) in seasonal allergic rhinitis
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Okubo K, Baba K. A double-blind non-inferiority clinical study of montelukast, a cysteinyl leukotriene receptor 1 antagonist, compared with pranlukast in patients with seasonal allergic rhinitis. Allergol Int. 2008 Dec;57(4):383-90. doi: 10.2332/allergolint.O-08-533. Epub 2008 Nov 1.
citation: Okubo K, Baba K. Therapeutic effect of montelukast, a cysteinyl leukotriene receptor 1 antagonist, on Japanese patients with seasonal allergic rhinitis. Allergol Int. 2008 Sep;57(3):247-55. doi: 10.2332/allergolint.O-07-515. Epub 2008 Jul 1.
Clinical trial NCT05170386: Cognitive Training on Sleeping Disorders in Stroke
Official title: Effect of Cognitive Training on Sleeping Disorders in Stroke: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Sleep Disorder
Keywords: Stroke
sleep disorders
cognition
Lead sponsor: October 6 University
Sponsor class: OTHER
First posted: 2021-12-28
Enrollment: 40
Sex: ALL
Minimum age (years): 40
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: group A (20 patients): that will receive cognitive training combined with instructive conventional treatment for sleeping disorder, and group B (20 patients): that will receive instructive conventional treatment for sleeping disorder
Primary purpose: TREATMENT

Brief summary: Cognitive impairment and sleeping disturbance following stroke diagnosis are common symptoms that significantly affect the quality of life.

Detailed description: 40 patients from both sexes will participate in this study. All the patients have to be diagnosed as stroke patients. The patients will be divided into two groups; group A (20 patients): which will receive cognitive training combined with instructive conventional treatment for a sleeping disorder, and group B (20 patients): which will receive instructive conventional treatment for sleeping disorder all the patients will be assessed pre and post-treatment using 1- Epworth sleeping scale, 2-Pittsburgh sleep quality index ( PSQI) 3- MINI mental cognitive scale

Eligibility criteria: Inclusion Criteria:

* stroke onset at least 5 months prior to study enrolment
* with sleeping disturbance
* age will range from 40:55
* upper extremity spasticity ranging from
* according to Modified Ashowrth Scale.

Exclusion Criteria:

* difficulty to communicate
* other neurological conditions that cause sleeping disorders
* severe depression or other psychiatric symptoms.

Primary outcomes:
measure: Epworth sleeping scale (ESS)
timeFrame: 4 weeks
measure: Pittsburgh sleep quality index ( PSQI)
timeFrame: 4 weeks
Secondary outcomes:
measure: The Mini-Mental State Examination (MMSE)
timeFrame: four weeks
Other outcomes:
Locations:
city: Al Jīzah
country: Egypt
facility: Lama S Mahmoud
state: Select State
Study officials:
References:
Clinical trial NCT03666286: Prospective Registry of Mobilization-, Routine- and Outcome Data of Intensive Care Patients
Official title: Prospective Registry of Mobilization-, Routine- and Outcome Data of Intensive Care Patients
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Critical Care
Rehabilitation
Outcome Assessment (Health Care)
Keywords: early mobilization, intensive care, longterm outcomes
Lead sponsor: Technical University of Munich
Sponsor class: OTHER
First posted: 2018-09-11
Enrollment: 10000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Intensive Care Unit Patients

Brief summary: Registry database of intensive care patients. These data comprises of routine data including mobilization data and follow up assessments.

Detailed description: Registry database of intensive care patients. These data comprises of routine data including mobilization data and follow up assessments.

The database is supposed to help quality improvement as well as

Eligibility criteria: Inclusion Criteria:

* Intensive care unit stay \> 24 hours

Exclusion Criteria:

-

Primary outcomes:
measure: Physical Function at hospital discharge
timeFrame: At hospital discharge, on average within 1 month
Secondary outcomes:
measure: Hospital Mortality
timeFrame: At hospital discharge, on average within 1 month
measure: Pre-ICU Function
timeFrame: 2 weeks before ICU admission
measure: Global function of the patient
timeFrame: 180 and 360 days after ICU discharge
measure: Physical function of the patient
timeFrame: 180 and 360 days after ICU discharge
measure: Quality of Life of the patient
timeFrame: 180 and 360 days after ICU discharge
measure: Cognitive Function
timeFrame: 180 and 360 days after ICU discharge
measure: Anxiety and Depression
timeFrame: 180 and 360 days after ICU discharge
measure: Return to work
timeFrame: 180 and 360 days after ICU discharge
measure: ICU Mortality
timeFrame: At ICU Discharge, on average within 2 weeks
measure: Physical function at ICU discharge
timeFrame: At ICU Discharge, on average within 2 weeks
Other outcomes:
measure: Disability-Free survival
timeFrame: 180 and 360 days after ICU discharge
Locations:
city: Munich
country: Germany
facility: Klinikum rechts der Isar der TUM
state: Bavaria
Study officials:
affiliation: Technical University of Munich
name: Stefan J Schaller, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00193986: Assessment of Prepulse Inhibition for Shock Pain Reduction
Official title: Assessment of Prepulse Inhibition for Shock Pain Reduction- Ventricular
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain Awareness From ICD Shocks
Keywords: Prepulse
Defibrillator
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
Collaborators: name: Dr. Douglas Cameron
name: Abbott Medical Devices
First posted: 2005-09-19
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 88
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: Patient tolerance of pain from discharges of implantable cardioverter defibrillators (ICD's) is highly variable. It can be influenced by psychological factors, physical condition and the number of shocks delivered.

It has been shown that cutaneous pain perception can be reduced by delivery of a weak , low voltage pulse (prepulse)prior to the delivery of a stronger shock.

A prepulse delivered before a high voltage ICD shock will decrease discomfort compared to a shock of equal energy without a prepulse.


Eligibility criteria: Inclusion Criteria:

18+ Approved indication for implantation of an ICD Able and willing to provide informed consent Independently complete and understand the Mini Mental State Evaluation

Exclusion Criteria:

Pregnancy Cannot understand English or French Contraindicated for defibrillation testing because of risk of thromboembolism Deaf or hard of hearing, making the acute testing difficult to conduct having pain or anxiety to the extent that, in the opinion of the investigator, the results would be confounded.

Having a Class I bradycardia pacing indication, requiring ongoing pacing support.

Visual problems which preclude reading the computer screen for the VAS test Severe musculoskeletal disorder that makes it difficult to undergo testing in the recumbent position Do not achieve a score \>24/30 on a Mini Mental State Exam

Primary outcomes:
measure: Assessment from pain perception from a shock preceded by a prepulse compared to a non prepulsed shock
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Toronto General Hospital
state: Ontario
Study officials:
affiliation: UHN
name: Douglas A Cameron, MD
role: PRINCIPAL_INVESTIGATOR
References: